{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:57:02Z","timestamp":1787871422033,"version":"build-2784847793"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Use of benzodiazepines (BZD) in patients receiving opioid agonist treatment (OAT) is common and associated with a variety of negative health and social outcomes. This cross-sectional study investigates the impact of BZD use in OAT patients on their quality of life (QoL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A convenience sample of patients receiving oral OAT or heroin-assisted treatment in two outpatient centres in Basel, Switzerland was investigated. Participants (n\u2009=\u2009141) completed self-report questionnaires on psychiatric symptoms and psychological distress (The Symptom Checklist 27, SCL-27), depressive state (German version of the Center for Epidemiological Studies Depression Scale), quality of life (Lancashire Quality of Life Profile, LQOLP) and use of BZD and other drugs (self-report questionnaire). Substance use was assessed by urine toxicology testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In bivariate analysis, total QoL scores were significantly lower for lifetime, current, and prolonged BZD users compared to participants without the respective use patterns. There was no significant relationship between BZD dose and QoL. In multivariable linear regression models controlling for psychiatric symptom load and depressive state, only lifetime use predicted lower QoL, whereas other BZD use patterns were not significantly associated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The association of lower QoL and BZD use in OAT patients is strongly confounded by co-occurring depressive state and psychiatric symptoms. Careful diagnosis and treatment of co-occurring mental disorders in OAT is paramount to improve QoL in this patient population and may also help reduce BZD use.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-023-00397-8","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T12:02:33Z","timestamp":1689681753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Benzodiazepine use, quality of life and psychiatric symptom burden in oral and injectable opioid agonist treatment: a cross-sectional study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1195","authenticated-orcid":false,"given":"Maximilian","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Gygli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean N.","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Undine E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"D\u00fcrsteler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"1","key":"397_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eurpsy.2011.11.003","volume":"28","author":"B Dell\u2019osso","year":"2013","unstructured":"Dell\u2019osso B, Lader M. Do benzodiazepines still deserve a major role in the treatment of psychiatric disorders? A critical reappraisal. Eur Psychiatry. 2013;28(1):7\u201320.","journal-title":"Eur Psychiatry"},{"issue":"4","key":"397_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/j.1360-0443.2006.01731.x","volume":"102","author":"S Nielsen","year":"2007","unstructured":"Nielsen S, Dietze P, Lee N, Dunlop A, Taylor D. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007;102(4):616\u201322.","journal-title":"Addiction"},{"issue":"1\u20132","key":"397_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0376-8716(98)00175-6","volume":"55","author":"M Gelkopf","year":"1999","unstructured":"Gelkopf M, Bleich A, Hayward R, Bodner G, Adelson M. Characteristics of benzodiazepine abuse in methadone maintenance treatment patients: a 1 year prospective study in an Israeli clinic. Drug Alcohol Depend. 1999;55(1\u20132):63\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"397_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1300\/J069v24n04_02","volume":"24","author":"M Backmund","year":"2008","unstructured":"Backmund M, Meyer K, Henkel C, Soyka M, Reimer J, Sch\u00fctz CG. Co-consumption of benzodiazepines in heroin users, methadone-substituted and codeine-substituted patients. J Addict Dis. 2008;24(4):17\u201329.","journal-title":"J Addict Dis"},{"issue":"1","key":"397_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-016-0127-9","volume":"14","author":"AM Franklyn","year":"2017","unstructured":"Franklyn AM, Eibl JK, Gauthier G, Pellegrini D, Lightfoot NK, Marsh DC. The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. Harm Reduct J. 2017;14(1):1\u20139.","journal-title":"Harm Reduct J"},{"issue":"1","key":"397_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-244X-11-90","volume":"11","author":"KW Chen","year":"2011","unstructured":"Chen KW, Berger CC, Forde DP, D\u2019Adamo C, Weintraub E, Gandhi D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry. 2011;11(1):1\u20137.","journal-title":"BMC Psychiatry"},{"issue":"1\u20132","key":"397_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.drugalcdep.2011.05.037","volume":"119","author":"M Vogel","year":"2011","unstructured":"Vogel M, D\u00fcrsteler-MacFarland KM, Walter M, Strasser J, Fehr S, Prieto L, et al. Prolonged use of benzodiazepines is associated with childhood trauma in opioid-maintained patients. Drug Alcohol Depend. 2011;119(1\u20132):93\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"397_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.drugalcdep.2010.06.013","volume":"112","author":"FJ Eiroa-Orosa","year":"2010","unstructured":"Eiroa-Orosa FJ, Haasen C, Verthein U, Dilg C, Sch\u00e4fer I, Reimer J. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend. 2010;112(3):226\u201333.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"397_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/10550880802122620","volume":"27","author":"B Brands","year":"2008","unstructured":"Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis. 2008;27(3):37\u201348.","journal-title":"J Addict Dis"},{"issue":"190","key":"397_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.drugalcdep.2018.05.030","volume":"1","author":"L Briand Madrid","year":"2018","unstructured":"Briand Madrid L, Morel S, Ndiaye K, Mezaache S, Rojas Castro D, Mora M, et al. Factors associated with perceived loss of libido in people who inject opioids: results from a community-based survey in France. Drug Alcohol Depend. 2018;1(190):121\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"174","key":"397_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.01.013","volume":"1","author":"T Abrahamsson","year":"2017","unstructured":"Abrahamsson T, Berge J, \u00d6jehagen A, H\u00e5kansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment\u2014a nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;1(174):58\u201364.","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"397_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.drugalcdep.2008.07.017","volume":"99","author":"E Lavie","year":"2009","unstructured":"Lavie E, Fats\u00e9as M, Denis C, Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: Correlates of use, abuse and dependence. Drug Alcohol Depend. 2009;99(1\u20133):338\u201344.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"397_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-018-0187-9","volume":"14","author":"L Strada","year":"2019","unstructured":"Strada L, Schmidt CS, Rosenkranz M, Verthein U, Scherbaum N, Reimer J, et al. Factors associated with health-related quality of life in a large national sample of patients receiving opioid substitution treatment in Germany: a cross-sectional study. Subst Abuse Treat Prev Policy. 2019;14(1):1\u201314.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"397_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-020-00309-y","volume":"15","author":"CF Aas","year":"2020","unstructured":"Aas CF, Vold JH, Skurtveit S, Lim AG, Ruths S, Islam K, et al. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Subst Abuse Treat Prev Policy. 2020;15(1):1\u201312.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"10","key":"397_CR15","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.addbeh.2013.05.008","volume":"38","author":"M Vogel","year":"2013","unstructured":"Vogel M, Kn\u00f6pfli B, Schmid O, Prica M, Strasser J, Prieto L, et al. Treatment or \u201chigh\u201d: benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav. 2013;38(10):2477\u201384.","journal-title":"Addict Behav"},{"issue":"68","key":"397_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsat.2016.06.008","volume":"1","author":"MD Stein","year":"2016","unstructured":"Stein MD, Kanabar M, Anderson BJ, Lembke A, Bailey GL. Reasons for benzodiazepine use among persons seeking opioid detoxification. J Subst Abuse Treat. 2016;1(68):57\u201361.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"397_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jsat.2009.03.006","volume":"37","author":"M Fats\u00e9as","year":"2009","unstructured":"Fats\u00e9as M, Lavie E, Denis C, Auriacombe M. Self-perceived motivation for benzodiazepine use and behavior related to benzodiazepine use among opiate-dependent patients. J Subst Abuse Treat. 2009;37(4):407\u201311.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"397_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/10673229709030550","volume":"4","author":"EJ Khantzian","year":"1997","unstructured":"Khantzian EJ. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv Rev Psychiatry. 1997;4(5):231\u201344.","journal-title":"Harv Rev Psychiatry"},{"issue":"3","key":"397_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jsat.2009.12.003","volume":"38","author":"M Fats\u00e9as","year":"2010","unstructured":"Fats\u00e9as M, Denis C, Lavie E, Auriacombe M. Relationship between anxiety disorders and opiate dependence\u2014 a systematic review of the literature: implications for diagnosis and treatment. J Subst Abuse Treat [Internet]. 2010;38(3):220\u201330.","journal-title":"J Subst Abuse Treat [Internet]."},{"issue":"11","key":"397_CR20","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1360-0443.2010.02933.x","volume":"105","author":"M Liebrenz","year":"2010","unstructured":"Liebrenz M, Boesch L, Stohler R, Caflisch C. Agonist substitution\u2014a treatment alternative for high-dose benzodiazepine-dependent patients? Addiction. 2010;105(11):1870\u20134.","journal-title":"Addiction"},{"issue":"11","key":"397_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002965","volume":"16","author":"J Macleod","year":"2019","unstructured":"Macleod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, et al. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med. 2019;16(11): e1002965.","journal-title":"PLoS Med"},{"issue":"5","key":"397_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/add.14886","volume":"115","author":"TW Park","year":"2020","unstructured":"Park TW, Larochelle MR, Saitz R, Wang N, Bernson D, Walley AY. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction. 2020;115(5):924\u201332.","journal-title":"Addiction"},{"key":"397_CR23","doi-asserted-by":"publisher","first-page":"108455","DOI":"10.1016\/j.jsat.2021.108455","volume":"131","author":"TW Park","year":"2021","unstructured":"Park TW, Sikov J, della Bitta V, Saitz R, Walley AY, Drainoni ML. \u201cIt could potentially be dangerous\u2026 but nothing else has seemed to help me.\u201d: Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. J Subst Abuse Treat. 2021;131:108455.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"397_CR24","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.addbeh.2004.03.003","volume":"29","author":"H Vorma","year":"2004","unstructured":"Vorma H, Naukkarinen H, Sarna S, Kuoppasalmi K. Symptom severity and quality of life after benzodiazepine withdrawal treatment in participants with complicated dependence. Addict Behav. 2004;29(6):1059\u201365.","journal-title":"Addict Behav"},{"key":"397_CR25","unstructured":"Schmid O. Einfluss einer Substitutionsbehandlung auf die Lebensqualit\u00e4t. Herbert Utz Verlag GmbH; 2014. 1\u2013275 p."},{"issue":"2","key":"397_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/eujp.2001.0231","volume":"5","author":"J Hardt","year":"2001","unstructured":"Hardt J, Gerbershagen HU. Cross-validation of the SCL-27: a short psychometric screening instrument for chronic pain patients. Eur J Pain. 2001;5(2):187\u201397.","journal-title":"Eur J Pain"},{"issue":"2","key":"397_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000368572","volume":"21","author":"U Verthein","year":"2015","unstructured":"Verthein U, Beck T, Haasen C, Reimer J. Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res. 2015;21(2):97\u2013104.","journal-title":"Eur Addict Res"},{"issue":"2","key":"397_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/13651501003660484","volume":"14","author":"HC Kuhl","year":"2010","unstructured":"Kuhl HC, Hartwig I, Petitjean S, M\u00fcller-Spahn F, Margraf J, Bader K. Validation of the Symptom Checklist SCL-27 in psychiatric patients: Psychometric testing of a multidimensional short form. Int J Psychiatry Clin Pract. 2010;14(2):145\u20139. https:\/\/doi.org\/10.3109\/13651501003660484.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"3","key":"397_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"LS Radloff","year":"1977","unstructured":"Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385\u2013401.","journal-title":"Appl Psychol Meas"},{"issue":"2","key":"397_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1026\/0012-1924.54.2.61","volume":"54","author":"D Lehr","year":"2008","unstructured":"Lehr D, Hillert A, Schmitz E, Sosnowsky N. Screening depressiver St\u00f6rungen mittels Allgemeiner Depressions-Skala (ADS-K) und State-Trait Depressions Scales (STDS-T). Diagnostica. 2008;54(2):61\u201370.","journal-title":"Diagnostica"},{"issue":"2","key":"397_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/archpsyc.63.2.219","volume":"63","author":"J Poling","year":"2006","unstructured":"Poling J, Oliveto A, Petry N, Sofuoglu M, Gonsai K, Gonzalez G, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006;63(2):219\u201328.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"397_CR32","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/ajad.12641","volume":"26","author":"M Romero-Gonzalez","year":"2017","unstructured":"Romero-Gonzalez M, Shahanaghi A, DiGirolamo GJ, Gonzalez G. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders. Am J Addict. 2017;26(8):838\u201344.","journal-title":"Am J Addict"},{"issue":"4","key":"397_CR33","first-page":"140","volume":"22","author":"S Priebe","year":"1995","unstructured":"Priebe S, Gruyters T, Heinze M, Hoffmann C, Jakel A. Subjektive Evaluationskriterien in der psychiatrischen Versorgung\u2014Erhebungsmethoden f\u00fcr Forschung und Praxis. Psychiatr Prax. 1995;22(4):140\u20134.","journal-title":"Psychiatr Prax"},{"issue":"2","key":"397_CR34","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/BF00788924","volume":"32","author":"JPJ Oliver","year":"1997","unstructured":"Oliver JPJ, Huxley PJ, Priebe S, Kaiser W. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol. 1997;32(2):76\u201383.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"1","key":"397_CR35","first-page":"1","volume":"3","author":"SM Giacomuzzi","year":"2001","unstructured":"Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Richter R, R\u00f6ssler H, et al. Lebensqualit\u00e4t: methadon vs. retardiertes Morphinsulfat\u2014eine Vergleichsstudie. Suchtmedizin. 2001;3(1):1\u20137.","journal-title":"Suchtmedizin."},{"issue":"6","key":"397_CR36","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1046\/j.1365-2524.2002.00394.x","volume":"10","author":"J Schneider","year":"2002","unstructured":"Schneider J, Wooff D, Carpenter J, Brandon T, McNiven F. Community mental healthcare in England: associations between service organisation and quality of life. Health Soc Care Community. 2002;10(6):423\u201334.","journal-title":"Health Soc Care Community"},{"issue":"2","key":"397_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/14999013.2021.1934195","volume":"21","author":"N Van Hecke","year":"2021","unstructured":"Van Hecke N, Meulewaeter F, Rowaert S, van Nieuwenhuizen C, Van Damme L, Vanderplasschen W, et al. Adolescents\u2019 quality of life and mental health needs during the initial phase in a closed institution. Int J Forensic Ment Health. 2021;21(2):107\u201319.","journal-title":"Int J Forensic Ment Health"},{"key":"397_CR38","doi-asserted-by":"crossref","unstructured":"Beubler E, Haltmayer H, Springer A. Opiatabh\u00e4ngigkeit: interdisziplin\u00e4re Aspekte f\u00fcr die Praxis. Springer-Verlag; 2007. 185\u2013204 p.","DOI":"10.1007\/978-3-211-69389-6"},{"issue":"3","key":"397_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","volume":"18","author":"H Ashton","year":"2005","unstructured":"Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005;18(3):249\u201355.","journal-title":"Curr Opin Psychiatry"},{"key":"397_CR40","unstructured":"Poser W, Poser S. Medikamente-Mi\u00dfbrauch und Abh\u00e4ngigkeit: Entstehung-Verlauf-Behandlung; 17 Tabellen. Thieme; 1996."},{"issue":"12","key":"397_CR41","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1080\/10826080500260800","volume":"40","author":"J Bizzarri","year":"2009","unstructured":"Bizzarri J, Rucci P, Vallotta A, Girelli M, Scandolari A, Zerbetto E, et al. Dual diagnosis and quality of life in patients in treatment for opioid dependence. Subst Use Misuse. 2009;40(12):1765\u201376.","journal-title":"Subst Use Misuse"},{"issue":"6","key":"397_CR42","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3109\/10550490903205652","volume":"18","author":"PJ Carpentier","year":"2009","unstructured":"Carpentier PJ, Krabbe PFM, Van Gogh MT, Knapen LJM, Buitelaar JK, De Jong CAJ. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict. 2009;18(6):470\u201380.","journal-title":"Am J Addict"},{"issue":"1","key":"397_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/ijerph14010038","volume":"14","author":"S Tamburin","year":"2017","unstructured":"Tamburin S, Federico A, Faccini M, Casari R, Morbioli L, Sartore V, et al. Determinants of quality of life in high-dose benzodiazepine misusers. Int J Environ Res Public Health. 2017;14(1):38.","journal-title":"Int J Environ Res Public Health"},{"key":"397_CR44","unstructured":"Bandelow B, Aden I, Alpers GW, Benecke A, Benecke C, Deckert J, et al. S3-Leitlinie Behandlung von Angstst\u00f6rungen: Version 2. 2021."},{"issue":"4","key":"397_CR45","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1046\/j.1440-1614.2003.01211.x","volume":"37","author":"T Weizman","year":"2016","unstructured":"Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A. Treatment of benzodiazepine dependence in methadone maintenance treatment patients: a comparison of two therapeutic modalities and the role of psychiatric comorbidity. Aust N Z J Psychiatry. 2016;37(4):458\u201363.","journal-title":"Aust N Z J Psychiatry"},{"issue":"4","key":"397_CR46","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/16506073.2017.1304445","volume":"46","author":"SG Hofmann","year":"2017","unstructured":"Hofmann SG, Curtiss J, Carpenter JK, Kind S. Effect of treatments for depression on quality of life: a meta-analysis. Cogn Behav Ther. 2017;46(4):265\u201386.","journal-title":"Cogn Behav Ther"},{"issue":"4","key":"397_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/15504263.2021.1979349","volume":"17","author":"KN Tormohlen","year":"2021","unstructured":"Tormohlen KN, Mojtabai R, Seiwell A, McGinty EE, Stuart EA, Tobin KE, et al. Co-occurring opioid use and depressive disorders: patient characteristics and co-occurring health conditions. J Dual Diagn. 2021;17(4):296\u2013303.","journal-title":"J Dual Diagn"},{"issue":"2","key":"397_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15504263.2020.1726549","volume":"16","author":"MF Ghabrash","year":"2020","unstructured":"Ghabrash MF, Bahremand A, Veilleux M, Blais-Normandin G, Chicoine G, Sutra-Cole C, et al. Depression and outcomes of methadone and buprenorphine treatment among people with opioid use disorders: a literature review. J Dual Diagn. 2020;16(2):191\u2013207.","journal-title":"J Dual Diagn"},{"issue":"18","key":"397_CR49","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","volume":"18","author":"M Dematteis","year":"2017","unstructured":"Dematteis M, Auriacombe M, D\u2019Agnone O, Somaini L, Szerman N, Littlewood R, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017;18(18):1987\u201399.","journal-title":"Expert Opin Pharmacother"},{"key":"397_CR50","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/19371918.2013.774673","volume":"28","author":"TM Kelly","year":"2013","unstructured":"Kelly TM, Daley DC. Integrated treatment of substance use and psychiatric disorders. Soc Work Public Health. 2013;28:388.","journal-title":"Soc Work Public Health"},{"key":"397_CR51","doi-asserted-by":"crossref","unstructured":"Hunt GE, Siegfried N, Morley K, Brooke-Sumner C, Cleary M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev. 2019;2019(12).","DOI":"10.1002\/14651858.CD001088.pub4"},{"issue":"1","key":"397_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-021-03188-0","volume":"21","author":"R Alsuhaibani","year":"2021","unstructured":"Alsuhaibani R, Smith DC, Lowrie R, Aljhani S, Paudyal V. Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: a systematic review. BMC Psychiatry. 2021;21(1):1\u201323.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"397_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0376-8716(99)00106-4","volume":"59","author":"ST Chermack","year":"2000","unstructured":"Chermack ST, Roll J, Reilly M, Davis L, Kilaru U, Grabowski J. Comparison of patient self-reports and urinalysis results obtained under naturalistic methadone treatment conditions. Drug Alcohol Depend. 2000;59(1):43\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"134","key":"397_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108555","volume":"1","author":"B Shadloo","year":"2022","unstructured":"Shadloo B, Baheshmat S, Rostam-Abadi Y, Shakeri A, Gholami J, Rahimi-Movaghar A. Comparison of self-reported substance use with biological testing among treatment-seeking patients with opioid use disorder. J Subst Abuse Treat. 2022;1(134): 108555.","journal-title":"J Subst Abuse Treat"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00397-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00397-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00397-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T12:05:53Z","timestamp":1689681953000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00397-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00397-8","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the responsible ethics committee (EKNZ, project ID: 2019-011152). The study was conducted in accordance with the Declaration of Helsinki and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}